Clinical trials: Pharmacotherapy
Edema, Erythema
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
This phase II trial studies how well pembrolizumab works in treating patients with stage IV inflammatory breast cancer or triple-negative breast cancer that has spread to other places in the body (metastatic) or has come back…
- Conditions
- Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative
- Trial name
- NCT02411656
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- M.D. Anderson Cancer Center
Colon Cancer Stage II
Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation
The CIRCULATE study evaluates the adjuvant therapy in patients with colon cancer UICC stage II. The primary aim of the study is to compare the disease free survival in patients who are positive for postoperative circulating…
- Trial name
- CIRCULATE (NCT04089631)
- Testing
- Capecitabine
- Where
- Germany
- Volunteers
- 4,812 people
- Sponsor
- Technische Universität Dresden
Cardiac Toxicity, Sarcoma
Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003937
- Testing
- cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride
- Where
- 148 sites in United States, Australia and 4 more
- Volunteers
- 253 people
- Sponsor
- Children's Oncology Group
Leukemia, Promyelocytic, Acute
APL93: Timing of CxT and Role of Maintenance
Objectives of the trial were to assess the optimal timing of chemotherapy with or after ATRA and the role of maintenance therapy.
- Trial name
- NCT00599937
- Testing
- ATRA, ATRA and or Chemo as maintenance
- Volunteers
- 576 people
- Sponsor
- Groupe d'etude et de travail sur les leucemies aigues promyelocytaires
Hepatocellular Carcinoma
HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC
Zoledronic acid was initially used for bone metastases in various malignancies. However, it is unknown whether hepatic arterial infusion chemotherapy combined with zoledronic acid can improve overall survival of unresectable…
- Trial name
- NCT05866172
- Testing
- HAIC, Zoledronic acid
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, fluorouracil, and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00095875
- Testing
- carboplatin, cisplatin, docetaxel
- Where
- 15 sites in United States, Germany
- Volunteers
- 145 people
- Sponsor
- Dana-Farber Cancer Institute
Gastric Cancer, Neoadjuvant Chemotherapy
Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
DRAGON III research, Neoadjuvant Chemotherapy (FLOT versus SOX) for Gastric Cancer, is an investigator initiated; phase 3, open label, multi-center randomized controlled study.
- Trial name
- NCT04384601
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Ruijin Hospital
Breast Cancer, Male Breast Cancer
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
Tipifarnib may stop the growth of breast cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT00470301
- Testing
- tipifarnib, paclitaxel, doxorubicin
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients
Breast cancer is one of the most prevalent cancers among women, and represents 20 - 25% of all female cancers. Despite earlier diagnosis and improvement in adjuvant therapies, some patients will present metastatic recurrence.
- Trial name
- FUMANCE (NCT02383030)
- Testing
- Fulvestrant
- Where
- 20 sites in Italy
- Volunteers
- 156 people
- Sponsor
- Consorzio Oncotech
Breast Cancer, HER2-positive Breast Cancer
RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer
This is a single-arm exploratory study to explore the effect of RC48 in HER2-positive neoadjuvant therapy and evaluate the non-inferiority of RC48 by comparing the latest reported data of T-DM1 in neoadjuvant therapy.
- Trial name
- NCT05134519
- Testing
- Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC)
- Volunteers
- 20 people
- Sponsor
- Xijing Hospital
Non-seminomatous Germ-cell Tumors
A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors
Cabazitaxel is a new generation taxane with a high capacity for blood-brain barrier crossing and limited peripheral neuro-toxicity, two major potential advantages in patients with advanced NSGCTs.
- Trial name
- CABA-GCT (NCT02115165)
- Testing
- Cabazitaxel
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Colorectal Neoplasm, Colorectal Cancer
NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer
The main clinical hypothesis is that compared to radio-chemotherapy for low and mid rectal tumors or surgery for high rectal tumors neoadjuvant chemotherapy reduces the rate of distant relapse without increasing the rate of local…
- Conditions
- Colorectal Neoplasm, Colorectal Cancer, Rectal Neoplasms, Chemotherapy Effect
- Trial name
- NEOLAR (NCT03280407)
- Testing
- Capecitabine, FOLFOX regimen (oxaliplatin/leucovorin/5FU), CAPOX (oxaliplatin/capecitabine)
- Where
- Denmark
- Volunteers
- 124 people
- Sponsor
- Zealand University Hospital
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
This phase II clinical trial tests a chemotherapy regimen (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin with or without rituximab [DA-EPOCH+/-R]) with the addition of targeted therapy…
- Trial name
- NCT05453500
- Testing
- Cyclophosphamide, Doxorubicin, Etoposide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Washington
Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
The goal of this Phase 2 trial is to evaluate a non-surgical bladder-preserving treatment mode which consists of neoadjuvant chemotherapy plus anti-programmed cell death protein 1 (anti-PD-1) therapy followed by radiotherapy plus…
- Conditions
- Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy
- Trial name
- BCIRT-01 (NCT05975307)
- Testing
- Toripalimab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Sun Yat-sen University
Medication Safety
Pharmacist and Data Driven Quality Improvement in Primary Care
P-DQIP is an intervention to improve prescribing safety in primary care. The 'intervention' is a health board quality improvement programme that will be implemented across all practices in one National Health Service (NHS) board…
- Trial name
- P-DQIP (NCT03747107)
- Testing
- P-DQIP
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- University of Dundee
Cancer, Chemotherapy Effect
Effectiveness of Immersive Virtual Reality in Patients With Cancer
The goal of this clinical trial is to study the effects of Immersive Virtual Reality in patients with cancer undergoing chemotherapy.
- Conditions
- Cancer, Chemotherapy Effect, Anxiety, Fatigue
- Trial name
- NCT05629507
- Testing
- Virtual Reality
- Where
- Italy
- Volunteers
- 74 people
- Sponsor
- ASL Gallura - Ospedale Giovanni Paolo II
Cancer
Demographics, Clinical Outcomes, and Physician Attitudes in Patients Who Have Received The MiCK Assay (CorrectChemo)
Recently an automated test for measuring cancer cell death in the presence of chemotherapy has been developed. This test has been called the MiCK assay during the ten year development phase and is now called Correct Chemo.
- Trial name
- NCT02137811
- Testing
- MICK Assay
- Where
- 2 sites in United States, Canada
- Sponsor
- Pierian Biosciences
Ovarian Cancer, Relapses
Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma
The early relapse of ovarian cancer occurring within 6 months of chemotherapy including platinum regimen are called relapses 'platinum resistant' consecutively patients die quickly of their disease.
- Trial name
- ITOV04 (NCT01177501)
- Testing
- Topotecan
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Preliminary Effectiveness and Feasibility of Transcutaneous Acupoints Electrical Stimulation on Chemotherapy-induced Peripheral Neuropathy Among Children With Acute Lymphoblastic Leukemia
The first goal of this clinical trial is to assess the feasibility of transcutaneous acupoints electrical stimulation (TAES) on children with acute lymphoblastic leukemia (ALL).
- Trial name
- NCT07319481
- Testing
- Transcutaneous Acupoints Electrical Stimulation (TAES)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Hong Kong Polytechnic University
Wilms Tumor, Fibrosarcoma
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.
- Conditions
- Wilms Tumor, Fibrosarcoma, Carcinoma, Round Cell, Nasopharyngeal Cancer
- Trial name
- NCT00141765
- Testing
- Myeloablative Chemotherapy, Stem Cell Rescue
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center